Colorectal cancer mutations are associated with survival and recurrence after pulmonary metastasectomy

Abstract

Background and Objectives: While knowledge has grown extensively regarding the impact of mutations on colorectal cancer prognosis, their role in outcomes after pulmonary metastasectomy (PM) remains minimally understood. We sought to determine the prognostic role of mutant disease on survival and recurrence after metastasectomy.Methods: Patients with available tumor sequencing profiles who underwent PM for colorectal cancer at a single institution from 2011 to 2017 were reviewed. Various demographic and clinicopathologic factors, as well as mutational status, were tested in the Cox regression analyses to identify predictors of survival and disease-free survival (DFS).Results: A total of 130 patients met inclusion criteria, among whom 78 (60%) were male and the mean age was 57 years. The median survival time and 5-year survival rate were 58.2 months and 47%, respectively. A single pulmonary nodule was present in 54%.Disease recurrence occurred for 87 (67%) patients, including 75 (58%) who had at least one lung recurrence after metastasectomy at a median time to recurrence of 19.4 months.Upon multivariable analysis, RAS and TP53 mutations were associated with shorter survival DFS, while APC is associated with prolonged survival.Conclusions: After metastasectomy for colorectal cancer, mutations in RAS, TP53, and APC play an important role in survival and recurrence. K E Y W O R D S APC, colorectal cancer, genes, mutations, pulmonary metastases, RAS, TP53

Response to letter to the editor

“…We would like to thank the reader for taking interest in our report, and for providing us with an opportunity to expound upon our results . Indeed, we believe that a discussion regarding the assumptions of Kaplan‐Meier survival analyses may provide a helpful context by which the readership of The Journal of Surgical Oncology may critically analyze this and other original manuscripts.…”

KRAS and BRAF Mutations as survival prognostic factors for Metastatic Colorectal Cancer patients after Lung metastasectomy: A Systematic Review and Meta-Analysis

“…(95%CI:55%-58% , I 2 :97.6) for WT and mKRAS groups respectively. The overall prevalence of thoracic metastases based on four articles (24,25,27,28) was 20%(95%CI:16%-24% , I 2 :80.7) and 22%…”

Exosomes miR-22-3p Derived from Mesenchymal Stem Cells Suppress Colorectal Cancer Cell Proliferation and Invasion by Regulating RAP2B and PI3K/AKT Pathway

“…With the changes in the diet structure of the Chinese people, the incidence of CRC has been increasing, and it has become a major tumor that threatens the health of our population [ 2 ]. Because of the relatively insidious onset and the atypical early symptoms of CRC, most patients are in the advanced stage of clinical diagnosis and miss the best opportunity for treatment [ 3 ]. Although the existing diagnosis and treatment methods have continued to be improved, the overall prognosis and the 5-year survival rate of the patient are still poor [ 4 ].…”